451 related articles for article (PubMed ID: 22332206)
21. Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination.
Konstas AG; Papapanos P; Tersis I; Houliara D; Stewart WC
Ophthalmology; 2003 Jul; 110(7):1357-60. PubMed ID: 12867391
[TBL] [Abstract][Full Text] [Related]
22. Effects of topical hypotensive drugs on circadian IOP, blood pressure, and calculated diastolic ocular perfusion pressure in patients with glaucoma.
Quaranta L; Gandolfo F; Turano R; Rovida F; Pizzolante T; Musig A; Gandolfo E
Invest Ophthalmol Vis Sci; 2006 Jul; 47(7):2917-23. PubMed ID: 16799034
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the nocturnal effects of once-daily timolol and latanoprost on intraocular pressure.
Liu JH; Kripke DF; Weinreb RN
Am J Ophthalmol; 2004 Sep; 138(3):389-95. PubMed ID: 15364220
[TBL] [Abstract][Full Text] [Related]
24. Additive effect of dorzolamide on aqueous humor flow in patients receiving long-term treatment with timolol.
Wayman LL; Larsson LI; Maus TL; Brubaker RF
Arch Ophthalmol; 1998 Nov; 116(11):1438-40. PubMed ID: 9823342
[TBL] [Abstract][Full Text] [Related]
25. Effect on intraocular pressure during 24 hours after repeated administration of the fixed combination of latanoprost 0.005% and timolol 0.5% in patients with ocular hypertension.
Larsson LI
J Glaucoma; 2001 Apr; 10(2):109-14. PubMed ID: 11316092
[TBL] [Abstract][Full Text] [Related]
26. A comparison of once-daily morning vs evening dosing of concomitant latanoprost/timolol.
Konstas AG; Nakos E; Tersis I; Lallos NA; Leech JN; Stewart WC
Am J Ophthalmol; 2002 Jun; 133(6):753-7. PubMed ID: 12036665
[TBL] [Abstract][Full Text] [Related]
27. A comparative analysis of the effects of the fixed combination of timolol and dorzolamide versus latanoprost plus timolol on ocular hemodynamics and visual function in patients with primary open-angle glaucoma.
Siesky B; Harris A; Sines D; Rechtman E; Malinovsky VE; McCranor L; Yung CW; Zalish M
J Ocul Pharmacol Ther; 2006 Oct; 22(5):353-61. PubMed ID: 17076630
[TBL] [Abstract][Full Text] [Related]
28. Aqueous humor dynamics during the day and night in juvenile and adult rabbits.
Zhao M; Hejkal JJ; Camras CB; Toris CB
Invest Ophthalmol Vis Sci; 2010 Jun; 51(6):3145-51. PubMed ID: 20107172
[TBL] [Abstract][Full Text] [Related]
29. Comparison of dorzolamide and timolol as suppressors of aqueous humor flow in humans.
Wayman L; Larsson LI; Maus T; Alm A; Brubaker R
Arch Ophthalmol; 1997 Nov; 115(11):1368-71. PubMed ID: 9366665
[TBL] [Abstract][Full Text] [Related]
30. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components.
Strohmaier K; Snyder E; DuBiner H; Adamsons I
Ophthalmology; 1999 Dec; 106(12 Suppl):1-9. PubMed ID: 10598691
[TBL] [Abstract][Full Text] [Related]
31. Effects on aqueous flow of dorzolamide combined with either timolol or acetazolamide.
Toris CB; Zhan GL; Yablonski ME; Camras CB
J Glaucoma; 2004 Jun; 13(3):210-5. PubMed ID: 15118464
[TBL] [Abstract][Full Text] [Related]
32. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes.
Toris CB; Camras CB; Yablonski ME
Ophthalmology; 1993 Sep; 100(9):1297-304. PubMed ID: 8371915
[TBL] [Abstract][Full Text] [Related]
33. Combination of systemic acetazolamide and topical dorzolamide in reducing intraocular pressure and aqueous humor formation.
Rosenberg LF; Krupin T; Tang LQ; Hong PH; Ruderman JM
Ophthalmology; 1998 Jan; 105(1):88-92; discussion 92-3. PubMed ID: 9442783
[TBL] [Abstract][Full Text] [Related]
34. An eight-week, multicentric, randomized, interventional, open-label, phase 4, parallel comparison of the efficacy and tolerability of the fixed combination of timolol maleate 0.5%/brimonidine tartrate 0.2% versus fixed combination of timolol maleate 0.5%/dorzolamide 2% in patients with elevated intraocular pressure.
Hatanaka M; Grigera DE; Barbosa WL; Jordao M; Susanna R
J Glaucoma; 2008 Dec; 17(8):674-9. PubMed ID: 19092465
[TBL] [Abstract][Full Text] [Related]
35. Using diurnal intraocular pressure fluctuation to assess the efficacy of fixed-combination latanoprost/timolol versus latanoprost or timolol monotherapy.
Varma R; Hwang LJ; Grunden JW; Bean GW
Br J Ophthalmol; 2010 Jan; 94(1):80-4. PubMed ID: 19692375
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of Latanoprostene Bunod 0.024% Compared With Timolol 0.5% in Lowering Intraocular Pressure Over 24 Hours.
Liu JHK; Slight JR; Vittitow JL; Scassellati Sforzolini B; Weinreb RN
Am J Ophthalmol; 2016 Sep; 169():249-257. PubMed ID: 27457257
[TBL] [Abstract][Full Text] [Related]
37. 24-hour control of intraocular pressure with 2% dorzolamide/0.5% timolol fixed-combination ophthalmic solution in open-angle glaucoma.
Feldman RM; Stewart RH; Stewart WC; Jia G; Smugar SS; Galet VA
Curr Med Res Opin; 2008 Aug; 24(8):2403-12. PubMed ID: 18627642
[TBL] [Abstract][Full Text] [Related]
38. The efficacy and safety of dorzolamide as adjunctive therapy to timolol maleate gellan solution in patients with elevated intraocular pressure. Additivity Study Group.
Adamsons I; Clineschmidt C; Polis A; Taylor J; Shedden A; Laibovitz R
J Glaucoma; 1998 Aug; 7(4):253-60. PubMed ID: 9713783
[TBL] [Abstract][Full Text] [Related]
39. Effects of Topical Bimatoprost 0.01% and Timolol 0.5% on Circadian IOP, Blood Pressure and Perfusion Pressure in Patients with Glaucoma or Ocular Hypertension: A Randomized, Double Masked, Placebo-Controlled Clinical Trial.
Oddone F; Rossetti L; Tanga L; Berardo F; Ferrazza M; Michelessi M; Roberti G; Manni G; Centofanti M
PLoS One; 2015; 10(10):e0140601. PubMed ID: 26484767
[TBL] [Abstract][Full Text] [Related]
40. Intraocular pressure over 24 hours after repeated administration of latanoprost 0.005% or timolol gel-forming solution 0.5% in patients with ocular hypertension.
Larsson LI
Ophthalmology; 2001 Aug; 108(8):1439-44. PubMed ID: 11470697
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
